• Primary cell cultures of neurons with / without astrocytes infected with AAV or LV vectors coding mutated proteins implicated in the pathology
• Cortical neurons treated with PDC (glutamate transport inhibitor): chronic excitotoxicity model - Follow up of compounds modulating NMDA receptors
• NGF deprived septal cholinergic neurons: model for neurotrophic compounds
• Microfluidic compartmentalized neuron cultures: soma is in one compartment and axon in the another one, both compartments being connected to enable amyloid peptide treatment in each compartment

Aggregation, propagation in each compartment, cell survival

Cell survival, morphological changes, protein measurement, etc.

• Transgenic mouse models to study factors/drugs targeting amyloidosis (APP/PS1?E9, 3xTg, huAPP)
• Tauopathies (Rat): lentiviral / AAV – Tau or P301L or Tau fused to a pro-aggregating peptide
• AAV- hAPP + AAV-hPS1 (mouse and rat)

Neuropathological evaluation; 3D histology to evaluate local changes statistically; Local glucose consumption; Brain morphometry using high resolution MRI; Amyloid Plaques by Gadolinium-Stained MRI; Perfusion measurement by MRI and resting state fMRI measures; Behavioral changes; etc.

Aß40, Aß42 and Tau quantification, cognitive function (open field, Morris water maze), LTP, etc.

• Parenchymal inoculation of Alzheimer human brain in Microcebus murinus
• Tauopathies (Macaques): lentiviral or AAV vectors over-expressing different species of tau proteins (WT, P301L, wild-fused to a pro-aggregating peptide)

• Clinical investigation Center (Phase I and II), Biological resource center, stratified cohorts of patients